Reference9 articles.
1. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial;Paz-Ares;Lancet,2019
2. Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features;Ellis;J Am Acad Dermatol,2020
3. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance;Bhardwaj;Cutan Ocul Toxicol,2022
4. Risk of scleroderma according to the type of immune checkpoint inhibitors;Terrier;Autoimmun Rev,2020
5. Scleroderma-like skin changes induced by checkpoint inhibitor therapy;Tjarks;J Cutan Pathol,2018
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献